VTGN
NASDAQVistagen Therapeutics Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$0.23-0.01 (-2.83%)
01:45 PM07:45 PM
News · 26 weeks45-29%
2026-01-182026-07-12
Mix2390d
- SEC Filings9(39%)
- Other7(30%)
- Insider5(22%)
- Leadership1(4%)
- Earnings1(4%)
Latest news
25 items- INSIDERChief Legal Officer Adler Reid G. was granted 36,818 shares, increasing direct ownership by 153% to 60,868 units (SEC Form 4)4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
- INSIDERChief Financial Officer Tressler Nick B. was granted 11,712 shares (SEC Form 4)4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
- INSIDERPresident and CEO Singh Shawn was granted 36,818 shares, increasing direct ownership by 204% to 54,846 units (SEC Form 4)4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
- SECVistagen Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Vistagen Therapeutics, Inc. (0001411685) (Filer)
- PRVistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety DisorderFasedienol did not achieve statistically significant improvement on primary and secondary endpoints In a post-hoc analysis, fasedienol achieved a nominal statistically significant improvement on primary endpoint in patients with very severe social anxiety disorder Favorable safety and tolerability data were consistent with previous clinical trials Company plans to meet with FDA to discuss a potential registrational pathway for fasedienol involving a single future Phase 3 trial with the Liebowitz Social Anxiety Scale as the primary endpoint and confirmatory evidence from the PALISADE Program Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscien
- SECVistagen Therapeutics Inc. filed SEC Form 8-K: Leadership Update8-K - Vistagen Therapeutics, Inc. (0001411685) (Filer)
- SECSEC Form 10-K filed by Vistagen Therapeutics Inc.10-K - Vistagen Therapeutics, Inc. (0001411685) (Filer)
- SECVistagen Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Vistagen Therapeutics, Inc. (0001411685) (Filer)
- PRVistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate UpdateCompleted randomized portion of PALISADE-4 Phase 3 trial of fasedienol for the acute treatment of social anxiety disorder; topline results expected this month Completed randomized portion of fasedienol Phase 2 repeat dose study; topline results expected in third quarter 2026 Achieved minimum ICH E1 safety exposure recommendations across fasedienol clinical program Reported preliminary positive data from open-label extension portion of PALISADE-3 Phase 3 trial Received FDA "Study May Proceed" letter under refisolone Investigational New Drug (IND) application to support further clinical development in the U.S. for treatment of moderate to severe vasomotor symptoms (hot flashes) due to
- SECVistagen Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Vistagen Therapeutics, Inc. (0001411685) (Filer)
- PRVistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety DisorderVistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that the Company's clinical program for fasedienol nasal spray for the acute treatment of social anxiety disorder has achieved the minimum patient exposures as recommended under ICH E1, the international regulatory standard governing safety database exposure recommendations for drugs intended for long-term treatment (chronic or repeated intermittent use for longer than 6 months) of non-life-threatening conditions1. As of May 31, 2026, the Company estimates
- PRVistagen to Participate in Jefferies 2026 Global Healthcare ConferenceVistagen, a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that the Company will participate in the Jefferies 2026 Global Healthcare conference being held June 2-4, 2026, in New York City. The Company will host one-on-one meetings with institutional investors during the conference. Investors interested in scheduling a meeting with Vistagen are encouraged to contact their Jefferies representative. About Vistagen Vistagen (NASDAQ:VTGN) is a late clinical-stage biopharmaceutical company leveraging a deep understanding of nose-
- INSIDERSEC Form 4 filed by Chief Medical Officer Angelov Angel S4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
- INSIDERSEC Form 3 filed by new insider Angelov Angel S3 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
- SECVistagen Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Vistagen Therapeutics, Inc. (0001411685) (Filer)
- PRVistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical OfficerDr. Angelov brings extensive industry experience across multiple therapeutic areas Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Angel S. Angelov, MD, MBA, as Chief Medical Officer (CMO), effective May 18, 2026. "We are pleased to welcome Dr. Angelov to the Vistagen team," said President and Chief Executive Officer of Vistagen, Shawn Singh. "His two decades of leadership across clinical development and medical affairs, including roles at Karuna, Neurocrine, Novartis, and Teva, wil
- PRVistagen to Participate in the 2026 RBC Capital Markets Global Healthcare ConferenceVistagen, a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that President and Chief Executive Officer, Shawn Singh, will participate in a fireside chat at the RBC Capital Markets Global Healthcare conference on Wednesday, May 20, 2026, at 2:35 p.m. Eastern Time. The Company will also host one-on-one meetings during the conference. The live webcast link will be available in the Investors section of Vistagen's website, under the "Events" tab. A replay of the webcast will be archived on the Company's website following the presenta
- SECVistagen Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Vistagen Therapeutics, Inc. (0001411685) (Filer)
- PRVistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety DisorderFasedienol nasal spray has been well-tolerated in patients with social anxiety disorder with no new drug-related safety findings after as-needed use in daily life for up to 12 months Clinically relevant improvement in social anxiety over time was observed on both clinician-administered and patient-reported scales over four months Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced preliminary positive data from the ongoing open-label extension (OLE) portion of its PALISADE-3 Phase 3 study of fasedienol fo
- SECVistagen Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Vistagen Therapeutics, Inc. (0001411685) (Filer)
- PRVistagen Announces Completion of Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety DisorderTopline results for the randomized portion of PALISADE-4 are expected in the second quarter of 2026 Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced that the last patient has completed the last visit in the randomized, double-blind, placebo-controlled portion of PALISADE-4, the Company's Phase 3 clinical trial evaluating fasedienol nasal spray for the acute treatment of social anxiety disorder. The open label extension (OLE) portion of the PALISADE-4 study remains ongoing. "The completion of the random
- SECVistagen Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Vistagen Therapeutics, Inc. (0001411685) (Filer)
- PRVistagen Receives FDA "Study May Proceed" Letter Under its Refisolone IND Application, Enabling Further Phase 2 Clinical Development for the Treatment of Vasomotor Symptoms (Hot Flashes) due to MenopauseVistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced receipt of a "Study May Proceed" letter from the U.S. Food and Drug Administration (FDA) under its U.S. Investigational New Drug (IND) application for refisolone nasal spray, the Company's non-hormonal, non-systemic product candidate in Phase 2 development for treatment of moderate to severe vasomotor symptoms (VMS) (also known as "hot flashes") due to menopause. The FDA's Study May Proceed letter enables the Company to pursue further Phase 2 clinical develo
- SECVistagen Therapeutics Inc. filed SEC Form 8-K: Leadership Update8-K - Vistagen Therapeutics, Inc. (0001411685) (Filer)
- INSIDERSEC Form 4 filed by Tressler Nick B.4 - Vistagen Therapeutics, Inc. (0001411685) (Issuer)
VTGN FAQ
6 questionsWhat does Vistagen Therapeutics Inc. do?
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in preparation for Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety...Where does VTGN stock trade?
Vistagen Therapeutics Inc. (VTGN) is listed on NASDAQ.What sector and industry is VTGN in?
Vistagen Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about VTGN?
Vistagen Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Jefferies: Hold with a $90.00 price target on 2025-12-17.What companies are similar to VTGN?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare VTGN side-by-side with any of them on Quantisnow.How can I track VTGN on Quantisnow?
Quantisnow aggregates Vistagen Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow VTGN to receive live email and push alerts on every new disclosure.